



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0771  
Inventors: Bennett et al.  
Serial No.: 10/655,801  
Filing Date: September 5, 2003  
Examiner: Not Yet Assigned  
Group Art Unit: 1623  
Title: Antisense Modulation of Inducible Nitric  
Oxide Synthase Expression

I, Jane Massey Licata, Registration No. 32,257,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: November 19, 2004

Jane Massey Licata  
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)


are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: November 19, 2004

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce	Docket No. <b>ISPH-0771</b>	Serial No. <b>10/655,801</b>
	Applicant <b>Bennett et al.</b>	
	Filing Date <b>Sept. 5, 2003</b>	Group <b>1623</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AA	Branch A.D., "A good antisense molecule is hard to find", TIBS 1998 45-50
	AB	Hidetoshi et al., "Specific Inhibition of Nitric Oxide Production in Macrophages by Phosphorothioate Antisense Ologonucleotides", Journal of Pharmaceutical Sciences 1997 86(10):1079-1084 XP-002156509
	AC	Hogue et al., "Antisense Oligonucleotide (AS) to the Inducible Nitric Oxide Synthase mRNA Prevents the Lipopolysaccharide-induced Hyperactivity in Rag Mesenteric Arterioics", Circulation 1995 92(8):Suppl. 1751-1752
	AD	Lesoon-Wood et al., "Enhancement of methylcholanthrene-induced neoplastic transformation in murine C3H 10T1/2 fibroblasts by antisense phosphorothioate oligonucleotide sequences", Cancer Letters 1999 147:163-173
	AE	Miller P.S., "Development of Antisense and Antigene Oligonucleotide Analogs", Progress in Nucleic Acid Research and Molecular Biology 1996 52:261-291 XP009005909
	AF	Noiri et al., "Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells", Am. J. Physiol. 1996 270(3 part 1):C794-C802
	AG	Rothe et al., "Generation and Characterization of Inducible Nitric Oxide Synthase Deficient Macrophage Cell Lines", Biol. Chem. Hoppe-Seyler 1996 377:227-231
	AH	Scarfi et al., "Modified peptide nucleic acids are internalized in mouse macrophages RAW 264.7 and inhibit inducible nitric oxide synthase", FEBS Letters 1999 451:264-268
	AI	Thomae et al., "Antisense oligodeoxynucleotide to inducible nitric oxide synthase inhibits nitric oxide synthesis in rat pulmonary artery smooth muscle cells culture", Surgery 1993 114:272-277 XP-000866441

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b> List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce	Docket No. <b>ISPH-0771</b>	Serial No. <b>10/655,801</b>
	Applicant <b>Bennett et al.</b>	
	Filing Date <b>Sept. 5, 2003</b>	Group <b>1623</b>

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	BA	WO 94/23038	13-10-94	PCT	X	
	BB	WO/00/66725	9-11-00	PCT	English Abstract	

EXAMINER

DATE CONSIDERED